Novel compounds

Abstract

A selective IAP binder together with a linker moiety.

1 . An IAP binding moiety together with a linker moiety which is a linking group comprising a length of 4-16 atoms in shortest length. 
     
     
         2 . A compound of Formula (I);
   Target Protein Binder-Linker-IAP binder  (I)
   wherein   Linker is a linking group comprising a length of 4-16 atoms in shortest length, or a pharmaceutically acceptable salt thereof.   
     
     
         3 . A method of treating diseases and conditions mediated by the target protein in a subject comprising administering a therapeutically effective amount of a compound of Formula (I), according to  claim 2 , or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A combination comprising a compound of Formula (I), according to  claim 2 , or a pharmaceutically acceptable salt thereof, and at least one further therapeutic agent. 
     
     
         5 . A pharmaceutical composition comprising a combination of a compound of Formula (I), according to  claim 2 , or a pharmaceutically acceptable salt thereof, and at least one further therapeutic agent and one or more of pharmaceutically acceptable carriers, diluents and excipients. 
     
     
         6 . A method of treating diseases and conditions mediated by the target protein comprising administering to a human in need thereof a therapeutically effective amount of a combination comprising compound of Formula (I), according to  claim 2 , or a pharmaceutically acceptable salt thereof, and at least one further therapeutic agent. 
     
     
         7 . A method of degrading the target protein comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I), according to  claim 2 , or a pharmaceutically acceptable salt thereof.